t
EMV Capital plc reported that its portfolio company, PDS Biotechnology Corporation, in which EMVC holds a 2.8% direct holding, entered into securities purchase agreements. These agreements are for a registered direct offering of 7,330,121 shares of common stock (or equivalents) and warrants to purchase up to 7,330,121 shares, priced at $1.50 for institutional investors and $1.66 for certain PDSB directors. The offering is expected to generate approximately $11 million in gross proceeds upfront, with up to an additional $11 million upon full cash exercise of the warrants, and is expected to close on or about February 28, 2025.
| Date | 27 Feb 2025 |
| Time | 16:30:26 |
| Category | Corporate updates |
| ID | 7704Y |
For immediate release
EMV Capital plc
("EMVC" or the "Company")
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
$11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the Warrants
EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, reports that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) - a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, and in which it holds a 2.8% direct holding - has announced that it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of PDSB, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of PDS.
The closing of the Offering is expected to occur on or about February 28, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $11 million.
A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.
PDSB intends to use the net proceeds from the Offering for research and development expenses and general corporate purposes.
A full version of PDS Biotech's announcement can be accessed here:
-Ends-
For more information, please contact:
|
|
|
|
EMV Capital plc |
via Rosewood |
|
Ilian Iliev, CEO |
|
|
|
|
|
Panmure Liberum (UK) Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
|
|
|
Rosewood (Financial PR) |
+44 (0)20 7653 8702 |
|
John West / Llew Angus / Lily Pearce |
|
About EMV Capital plc (EMVC)
EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.
With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
· capital-efficient investments through Group balance sheet;
· fund management of the Evergreen EIS and Martlet Capital Funds;
· syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.